Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected] Learn more

HER2 WT Citations (20)

Plasmid Article: Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.
Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC Cancer Cell. 2004 Nov . 6(5):459-69.
PubMed Journal

Articles Citing HER2 WT

Articles
Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha. Merkhofer EC, Cogswell P, Baldwin AS. Oncogene. 2010 Feb 25. 29(8):1238-48. PubMed
Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells. Li YW, Zhu GY, Shen XL, Chu JH, Yu ZL, Fong WF. Cancer Chemother Pharmacol. 2011 Nov;68(5):1315-23. doi: 10.1007/s00280-011-1624-x. Epub 2011 Apr 3. PubMed
Role of epidermal growth factor receptor signaling in the interaction of Neisseria meningitidis with endothelial cells. Slanina H, Mundlein S, Hebling S, Schubert-Unkmeir A. Infect Immun. 2014 Mar;82(3):1243-55. doi: 10.1128/IAI.01346-13. Epub 2013 Dec 30. PubMed
Akt phosphorylates and activates HSF-1 independent of heat shock, leading to Slug overexpression and epithelial-mesenchymal transition (EMT) of HER2-overexpressing breast cancer cells. Carpenter RL, Paw I, Dewhirst MW, Lo HW. Oncogene. 2015 Jan 29;34(5):546-57. doi: 10.1038/onc.2013.582. Epub 2014 Jan 27. PubMed
Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells. Hosonaga M, Arima Y, Sugihara E, Kohno N, Saya H. Cancer Sci. 2014 Jul;105(7):779-87. doi: 10.1111/cas.12427. Epub 2014 Jun 2. PubMed
Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib. Huang W, Wu QD, Zhang M, Kong YL, Cao PR, Zheng W, Xu JH, Ye M. Cancer Lett. 2015 Jan 28;356(2 Pt B):862-71. doi: 10.1016/j.canlet.2014.10.040. Epub 2014 Nov 4. PubMed
Loss of FOXO1 promotes gastric tumour growth and metastasis through upregulation of human epidermal growth factor receptor 2/neu expression. Ko YS, Cho SJ, Park J, Kim Y, Choi YJ, Pyo JS, Jang BG, Park JW, Kim WH, Lee BL. Br J Cancer. 2015 Oct 20;113(8):1186-96. doi: 10.1038/bjc.2015.273. Epub 2015 Oct 8. PubMed
Type II cGMP-dependent protein kinase directly inhibits HER2 activation of gastric cancer cells. Zhu M, Yao X, Wu M, Qian H, Wu Y, Chen Y. Mol Med Rep. 2015 Dec 17. doi: 10.3892/mmr.2015.4688. PubMed
Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Ma S, Henson ES, Chen Y, Gibson SB. Cell Death Dis. 2016 Jul 21;7:e2307. doi: 10.1038/cddis.2016.208. PubMed
An in-vivo study for targeted delivery of copper-organic complex to breast cancer using chitosan polymer nanoparticles. Pramanik A, Laha D, Dash SK, Chattopadhyay S, Roy S, Das DK, Pramanik P, Karmakar P. Mater Sci Eng C Mater Biol Appl. 2016 Nov 1;68:327-337. doi: 10.1016/j.msec.2016.05.014. Epub 2016 May 10. PubMed
Let-7 Status is Crucial for PARP1 Expression in HER2-overexpressing Breast Tumors. Wielgos ME, Rajbhandari R, Cooper TS, Wei S, Nozell SE, Yang ES. Mol Cancer Res. 2016 Dec 28. pii: molcanres.0287.2016. doi: 10.1158/1541-7786.MCR-16-0287-T. PubMed
Establishment of a spontaneous metastasis tumor model for human ErbB-2 vaccine. Dai X, He Y, Yao W, Gao X. Biomed Pharmacother. 2017 Apr;88:991-998. doi: 10.1016/j.biopha.2017.01.099. Epub 2017 Feb 6. PubMed
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. Napolitano S, Martini G, Martinelli E, Belli V, Parascandolo A, Laukkanen MO, Sforza V, Morgillo F, Ciardiello D, Ciardiello F, Troiani T. Oncotarget. 2017 Jun 27. doi: 10.18632/oncotarget.18749. PubMed
Switching of the substrate specificity of protein tyrosine phosphatase N12 by cyclin-dependent kinase 2 phosphorylation orchestrating 2 oncogenic pathways. Li H, Yang D, Ning S, Xu Y, Yang F, Yin R, Feng T, Han S, Guo L, Zhang P, Qu W, Guo R, Song C, Xiao P, Zhou C, Xu Z, Sun JP, Yu X. FASEB J. 2018 Jan;32(1):73-82. doi: 10.1096/fj.201700418R. Epub 2017 Aug 24. PubMed
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. Napolitano S, Martini G, Martinelli E, Belli V, Parascandolo A, Laukkanen MO, Sforza V, Morgillo F, Ciardiello D, Ciardiello F, Troiani T. Oncotarget. 2017 Jun 27;8(40):67592-67604. doi: 10.18632/oncotarget.18749. eCollection 2017 Sep 15. PubMed
Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth. Carpenter RL, Sirkisoon S, Zhu D, Rimkus T, Harrison A, Anderson A, Paw I, Qasem S, Xing F, Liu Y, Chan M, Metheny-Barlow L, Pasche BC, Debinski W, Watabe K, Lo HW. Oncotarget. 2017 May 22;8(43):73947-73963. doi: 10.18632/oncotarget.18166. eCollection 2017 Sep 26. PubMed
Differential regulation of human monocytes and NK cells by antibody-opsonized tumors. Yin J, Albers AJ, Smith TS, Riddell GT, Richards JO. Cancer Immunol Immunother. 2018 Aug;67(8):1239-1250. doi: 10.1007/s00262-018-2179-z. Epub 2018 May 31. PubMed
Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Kurmi K, Hitosugi S, Yu J, Boakye-Agyeman F, Wiese EK, Larson TR, Dai Q, Machida YJ, Lou Z, Wang L, Boughey JC, Kaufmann SH, Goetz MP, Karnitz LM, Hitosugi T. Cell Metab. 2018 Dec 4;28(6):833-847.e8. doi: 10.1016/j.cmet.2018.08.008. Epub 2018 Aug 30. PubMed
Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells. Gao P, Wang X, Jin Y, Hu W, Duan Y, Shi A, Du Y, Song D, Yang M, Li S, Han B, Zhao G, Zhang H, Fan Z, Miao QR. Breast Cancer Res. 2018 Sep 12;20(1):112. doi: 10.1186/s13058-018-1028-5. PubMed
HER2 decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property in an NFkappaB-dependent way. Wang W, Gao Y, Hai J, Yang J, Duan S. Biosci Rep. 2019 Mar 19;39(3). pii: BSR20180829. doi: 10.1042/BSR20180829. Print 2019 Mar 29. PubMed

If you have published an article using this plasmid, please email us at [email protected] to have your article added to this page.